OGB 21504
Alternative Names: OGB-21504Latest Information Update: 15 Dec 2021
At a glance
- Originator Onegene Biotechnology
- Class Antibodies; Hepatoprotectants; Immunoconjugates; Obesity therapies; Recombinant fusion proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Non-alcoholic steatohepatitis; Obesity
Most Recent Events
- 07 Dec 2021 Early research in Non-alcoholic steatohepatitis in South Korea (Parenteral) before December 2021 (Onegene Biotechnology pipeline, December 2021)
- 07 Dec 2021 Early research in Obesity in South Korea (Parenteral) before December 2021 (Onegene Biotechnology pipeline, December 2021)